AptarGroup (ATR) Expected to Beat Earnings Estimates: Should You Buy?
AptarGroup (ATR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ATR - AptarGroup, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$158.00
DETAILS
HIGH:
$160.00
LOW:
$156.00
MEDIAN:
$158.00
CONSENSUS:
$158.00
UPSIDE:
19.37%
Stock News
Aptar Beauty Launches Next-Generation Auto-Loading Dropper Technology for Easier, More Accurate Skincare Dosing
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announces the first commercial launch of its innovative auto-loading, dosing dropper technology called NeoDropper Autoload. Aptar's technology is featured on Dermalogica's FutureCode Booster skincare product. Designed for prestige skincare and dermocosmetic brands, this next-generation dropper packaging is intended to address consumer needs around dosage control, convenience and clean usage by supporting precision dispensing and user experience.
Chicago Partners Investment Group LLC Invests $505,000 in AptarGroup, Inc. $ATR
Chicago Partners Investment Group LLC acquired a new stake in AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,051 shares of the industrial products company's stock, valued at approximately $505,000. A number of other
Aptar Declares Quarterly Dividend
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026.
Will AptarGroup (ATR) Beat Estimates Again in Its Next Earnings Report?
AptarGroup (ATR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
-- ATR 1072 is the company's first precision cardiology program to enter the clinic -- -- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease -- SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. "PRKAG2 syndrome and other rare genetic cardiomyopathies represent a profound unmet need — these are progressive, life-altering and life-threatening diseases that often strike early, affect multiple members of the same family, and have no approved therapy to address their root cause," said Kathleen Gallagher, President and Chief Executive Officer, Atrium Therapeutics.
Aptar Releases 2025 Corporate Sustainability Report
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Releases 2025 Corporate Sustainability Report.
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
AptarGroup, Inc. (ATR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
A Look at AptarGroup Inc (ATR) After 3.5% Gain -- GF Value $156.52 vs Price $115.90
On June 09, 2026, AptarGroup Inc (ATR) shares rose 3.5% today, currently priced at $115.90. The stock has experienced a 52-week range of $103.23 to $164.28, ref
AptarGroup, Inc. (ATR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
AptarGroup, Inc. (ATR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year.
Aptar to Participate in Upcoming Investor Conferences
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences.
AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
AptarGroup NYSE: ATR used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.
AptarGroup Q1 Earnings Beat Estimates but Decline Y/Y, Shares Dip 1%
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
Advanced Technology Recycling (ATR) Announces That They Are Now Offering Wholesale Electronics to the General Public Through Their Online Auction Site
ITAD Firm, Advanced Technology Recycling (ATR), now offers wholesale electronics and computers to the general public through our online auction platform.
Is AptarGroup Inc (ATR) a Bargain After 3.8% Drop? GF Value Says Undervalued
On May 01, 2026, AptarGroup Inc (ATR) shares fell 3.8% to a current price of $119.02. The stock has experienced significant volatility over the past year, with
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
AptarGroup (ATR) Beats Q1 Earnings and Revenue Estimates
AptarGroup (ATR) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.2 per share a year ago.
Aptar Reports First Quarter 2026 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports First Quarter 2026 Results.
Avery Dennison Q1 Earnings Top Estimates on Volume Gains, Cost Control
AVY beats Q1 earnings estimates on strong volumes and cost control, with profits rising and cash flow swinging to positive despite mixed segment performance.
Price Targets
AptarGroup price target raised to $160 from $150 at Raymond James
$160.00
(was $130.38)
Raymond James
AptarGroup price target raised to $156 from $145 at Baird
$156.00
(was $134.31)
Robert W. Baird
KeyBanc Reiterates Overweight Rating on AptarGroup (ATR)
$220.00
(was $124.56)
Paul Knight
·
KeyBanc
AptarGroup price target lowered to $145 from $160 at Baird
$145.00
(was $116.01)
Ghansham Panjabi
·
Robert W. Baird
AptarGroup price target lowered to $133 from $152 at Wells Fargo
$133.00
(was $116.01)
Wells Fargo
AptarGroup (ATR) PT Raised to $185 at Baird
$185.00
(was $169.63)
Ghansham Panjabi
·
Robert W. Baird
Jefferies Upgrades AptarGroup (ATR) to Buy
$215.00
(was $161.55)
Daniel Rizzo
·
Jefferies
Nutanix Set To Outperform With Strong FCF And Hybrid Cloud Focus, Despite Macro Challenges: Analyst
$45.00
(was $132.55)
Thomas Blakey
·
Loop Capital Markets
Morgan Stanley Maintains Equal-Weight on AptarGroup, Lowers Price Target to $120
$120.00
(was $108.20)
Morgan Stanley
Baird Maintains Neutral on AptarGroup, Lowers Price Target to $110
$110.00
(was $108.06)
Robert W. Baird
Wells Fargo Maintains Overweight on AptarGroup, Lowers Price Target to $125
$125.00
(was $99.81)
Wells Fargo
Aptar (ATR) Stock: $150 Price Target And Overweight Rating
$150.00
(was $113.39)
Gabe Hajde
·
Wells Fargo